This review aims to highlight the central role of OS in the pathophysiology of ALS, specifically focusing on the KEAP1-NRF2 system and its alteration in ALS, while discussing the potential applications of NRF2 activators in ALS therapy. The gene discussed is NFE2L2; the disease is amyotrophic lateral sclerosis.